Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeuroNOS secures funding for autism treatment development
The treatment, designed to be administered either as an injectable or an oral medication, utilises the regulation of the brain’s nitric oxide (NO) levels to influence neurological function.
The treatment, designed to be administered either as an injectable or an oral medication, utilises the regulation of the brain’s nitric oxide (NO) levels to influence neurological function.
The centre will focus on the early detection of diseases and design treatments for improved patient outcomes using precision medicine. Metabolomics, the study of small molecules or metabolites,
The therapy claims to be the only oral inhibitor targeting the alternative complement pathway, specifically addressing what is believed to be the root cause of the disease. Usually
This collaboration leverages Porton Advanced’s cell and gene therapy manufacturing offerings and Artemis cell receptor as well as the E‑ALPHA antibody discovery platforms of Eureka. Through this partnership, Porton Advanced
The investment also comprises C$60m in funding from the Canadian federal government. Delpharm will manufacture sterile injectable drugs at the Boucherville site and bolster its local supply chain. The
This one-time-day cream claims to offer a non-steroidal alternative that is tailored for quick relief from itch and inflammation, with a suitability for long-term usage. Arcutis Canada general
This investigational medicine is stated to be the “first” ribonucleic acid (RNA) editing development candidate from the company’s Oligonucleotide Promoted Editing of RNA (OPERA) platform. Korro Bio chief
Versamune is the company’s new investigational MUC1-targeted immunotherapy candidate. The therapy is intended for individuals who have failed prior treatments. PDS submitted the application to the US regulator
This initiative is stated to be a part of the company’s Phase I contract development and manufacturing organisation (CDMO) growth strategy. In response to the growing need for
The collaboration aims to explore this WEE1 kinase inhibitor for treating human papillomavirus + (HPV+) and HPV- HNSCC with specific genomic markers. As per the agreement, Aprea will